Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 5/20 | 0.45 |
| ▸ | CNR2 | P34972 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89360 | 0.97 | ALDH1A1 (0.66) | ALDH1A1TSHRL3MBTL1CNR1CNR2 | |
| SCHEMBL89675 | 0.93 | ALDH1A1 (0.68) | ALDH1A1TSHRL3MBTL1CNR1CNR2 | |
| SCHEMBL662852 | 0.88 | ALDH1A1 (0.59) | ALDH1A1TSHRL3MBTL1CNR1CNR2 | |
| SCHEMBL89319 | 0.87 | ALDH1A1 (0.49) | ALDH1A1TSHRL3MBTL1CNR1CNR2 | |
| SCHEMBL57079 | 0.86 | ALDH1A1 (0.86) | ALDH1A1TSHRL3MBTL1KDM4EPOLB | |
| SCHEMBL8265518 | 0.86 | CNR1 (0.55) | ALDH1A1TSHRL3MBTL1CNR1CNR2 | |
| SCHEMBL8265089 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TSHRL3MBTL1CNR1CNR2 | |
| SCHEMBL1073010 | 0.86 | ALDH1A1 (0.61) | ALDH1A1TSHRL3MBTL1CNR1CNR2 | |
| SCHEMBL10185688 | 0.85 | ALDH1A1 (0.48) | ALDH1A1TSHRL3MBTL1CNR1CNR2 | |
| SCHEMBL89739 | 0.84 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20080242662-A1 | Organic Compounds | NIHONYANAGI ATSUKO | 2008-10-02 | — | — | US | disclosed |
| US-20080242662-A1 | Organic Compounds | NIHONYANAGI ATSUKO | 2008-10-02 | — | — | US | disclosed |
| EP-1907359-A2 | 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1888569-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007006534-A2 | PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006128659-A2 | PIPERAZINE DERIVATIVE RENIN INHIBITORS. | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006125621-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006094763-A1 | 3,4,5-SUBSTITUTED PIPERIDINE COMPOUNDS | NOVARTIS AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242662-A1 | Organic Compounds | REN, ACE, ECE1 | ALDH1A1 13/4885TSHR 2291/4885L3MBTL1 3415/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | ALDH1A1 21/4885TSHR 2757/4885L3MBTL1 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.